Better medicine is in our(synthetic) DNA
Better medicine is in our(synthetic) DNA
A path to better medicines
With our novel DNA base pair, we are designing and building protein therapeutics to create an entirely new generation of tailored medicines to improve how we treat disease.
DNA research: the path to Synthorins™
1866
Mendel publishes on the heredity of peas and establishes the first laws of genetics.1944
Avery, McLeod, McCarty define DNA as the carrier of genetic information.1950
Chargaff establishes rules of base pairing.1953
Wilkins, Franklin, Watson, and Crick publish the double helix structure of DNA.1958
Hoagland and Zamecnik discover tRNA.1962
Rich publishes the first proposal of unnatural base pairs (UBP) and selective pairing of DisoC and DisoG via H-bonding patterns1964
Nirenberg, Leder, Khorana, and Holley describe triplet nature of the genetic code and genetic code translation.1973
Cohen and Boyer discover recombinant DNA technology.1983
Mullis invents the polymerase chain reaction (PCR) technique.1989
Benner demonstrates in vitro replication and transcription of isoC and isoG.1992
Benner publishes first in vitro translation using isoC–isoG pair and isoCAG codon.1997
Kool demonstrates selective dA-dF pairing with reduced complementary H-bonding.2003
Two scientific teams publish the first human genome sequences.2006
Hirao publishes first UBP pair that could be PCR amplified with an error rate below 1%.2009
Romesberg lab publishes first UBP pairs, d5SICS-dNaM (X) and d5SICS-dMMO2 (Y), that can be efficiently PCR amplified and transcribed.2014
Romesberg lab shows nucleotide transporter allows for replication of XY genetic information in E. coli.2014
Synthorx founded with technology licensed from the Romesberg Lab at The Scripps Research Institute and secures $6.25M Series A.2015
Demonstration of in vitro translation of UBPs (X and Y): Synthorx identifies codons and validates in vitro translation.2016
Synthorx completes $10M Series B and initiates in vivo platform and internal pipeline.2017
Synthorx initiates scalable recombinant protein production (synthorins) and begins lead candidate selection in two programs.2017
Romesberg lab publishes on a semi-synthetic organism that stores and retrieves increased genetic information.2018
Synthorx starts two IND-enabling programs.2018
Synthorx completes $63M Series C financing.2018
Synthorx raises $150.7 million in initial public offering. $THOR trading begins.2019
Synthorx opens HAMMER, a global, Phase 1/2, first-in-human clinical trial of THOR-707, with Australia being the first region to enroll patients. The company receives clearance from FDA for the IND Application for THOR-707, paving the way for enrollment to proceed in the US.
The Synthorx team
At Synthorx, we focus on making significant advancements in protein design to deliver optimized therapeutics – called Synthorins – to improve the lives of people with cancer and autoimmune disorders. While we are a diverse group of people as employees of Synthorx, together, we are one for patients.
| Title | Address | Description |
|---|---|---|
Synthorx, Inc. | 11099 N Torrey Pines Rd, La Jolla, CA 92037, USA |
|
